Immune imprinting as a barrier to effective COVID-19 vaccines

Julia N Faraone; Shan-Lu Liu

doi:10.1016/j.xcrm.2023.101291

Immune imprinting as a barrier to effective COVID-19 vaccines

Cell Rep Med. 2023 Nov 21;4(11):101291. doi: 10.1016/j.xcrm.2023.101291.

Authors

Julia N Faraone¹, Shan-Lu Liu²

Affiliations

¹ Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA; Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA.
² Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA; Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH 43210, USA; Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA. Electronic address: liu.6244@osu.edu.

Abstract

Wang and colleagues show that immune imprinting impairs neutralizing antibody titers for bivalent mRNA vaccination against SARS-CoV-2 Omicron subvariants. Imprinting from three doses of monovalent vaccine can be alleviated by BA.5 or BQ-lineage breakthrough infection but not by a bivalent booster.¹.

Publication types

Comment

MeSH terms

Breakthrough Infections
COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
RNA, Messenger
SARS-CoV-2 / genetics

Substances

COVID-19 Vaccines
RNA, Messenger